Merck & Co., Inc. Submits New Data to FDA for Widened Gardasil Use in Women 27 to 45

Bookmark and Share

Reuters -- Merck & Co (MRK.N) on Wednesday said it had provided U.S. regulators with new information needed for approval to market its Gardasil cervical cancer vaccine to women between the ages of 27 to 45.

Back to news